AI Insight: CBRE's current price exceeds the PERT-weighted fair value by 4.6%, indicating potential overvaluation amid divergent valuation methods, notably a low DCF midpoint versus higher P/E and analyst targets. Financial health scores reveal fair liquidity and profitability but weak growth and leverage. Monte Carlo analysis shows significant downside risk (88.9%) and high volatility, reflecting elevated investment risk.